Month: April 2024

NEWMARKET, Ontario, April 29, 2024 (GLOBE NEWSWIRE) — AirBoss of America Corp. (TSX: BOS) (OTCQX:ABSSF) (the “Company” or “AirBoss”) today announced that its wholly-owned subsidiary, AirBoss Defense Group (“ADG”), has been awarded a contract valued at up to US$45 million to provide its Bandolier lightweight, multipurpose energetic system to a NATO partner nation. Subject to satisfaction of customary conditions, including obtaining required export documentation, deliveries under this contract are expected to commence in the second half of 2024 and continue through to the end of 2025. The Bandolier is a lightweight and modular energetic system that can be employed across mobility, counter mobility, and survivability mission profiles. The Bandolier is designed to bridge the identified capability gap between large, complex, single...

XOLREMDI targets CXCR4 pathway dysfunction, the underlying cause of WHIM syndrome Breakthrough Therapy approval follows Priority Review of 4WHIM Phase 3 clinical trial data X4 granted Rare Pediatric Disease Priority Review Voucher (PRV) concurrent with approval Conference call and webcast to be hosted today at 8:30 am ET BOSTON, April 29, 2024 (GLOBE NEWSWIRE) — X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that the U.S. Food and Drug Administration (FDA) has approved XOLREMDI™ (mavorixafor) capsules for use in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes. XOLREMDI, a selective CXC chemokine...

LONDON, April 29, 2024 (GLOBE NEWSWIRE) — Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, and Journey Clinical, a leading psychedelic-assisted psychotherapy platform with the largest network of licensed therapists focused on psychedelics in the US, today announced they have entered into a research collaboration agreement to inform the development of a scalable and practical delivery and healthcare provider training model for COMP360 psilocybin treatment, if approved for treatment-resistant depression (TRD). The first phase of the collaboration comprises an in-depth information exchange on the COMP360 psilocybin treatment delivery model. Together, Compass and Journey Clinical will work to better understand the patient...

CHANTILLY, Va., April 29, 2024 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE: PSN) announced today that the company was awarded a position on an indefinite-delivery, indefinite-quantity (IDIQ) multiple award task order contract (MATOC) by the United States Army Environmental Command (USAEC) for remediation services at sites involving hazardous toxic waste, including perfluoroalkyl and polyfluoroalkyl substances (PFAS). The $464 million ceiling value contract consists of a five-year ordering period and is new work for the company. Under this contract, Parsons will compete for task orders to perform evaluation, investigation, and other remediation services at various U.S. Army installations throughout the country and territories. Activities include PFAS treatment, munitions response, and operational range assessments. “Parsons has...

SAMPO PLC                PRESS RELEASE        29 April 2024 at 1:10 pm Sampo Group’s results for January–March 2024 will be published on 7 May 2024 Sampo Group will publish the Interim Statement for January–March 2024 on 7 May between 9:30 am and 10:00 am Finnish time (7:30–8:00 am UK time). The report, Investor Presentation and a video review with Group CFO Knut Arne Alsaker will be available at www.sampo.com/result. Conference call 7 May at 2:30 pm Finnish time (12:30 pm UK time)Tel. +1 786 697 3501, +44 (0) 33 0551 0200, +46 (0) 8 5052 0424, or +358 (0)9 2319 5437. Conference passcode: Sampo Q1 Group CEO Torbjörn Magnusson, Group CFO Knut Arne Alsaker, CEO of If P&C Morten Thorsrud, and Head of IR Sami Taipalus will attend the conference call for investors and analysts. The conference call can also be followed live at www.sampo.com/result....

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 29, 2024 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for MNKD-101 (Clofazimine Inhalation Suspension), enabling the initiation of a Phase 3 study for the treatment of nontuberculous mycobacterial (NTM) lung disease. “Oral clofazimine has been utilized as a treatment option for patients living with NTM lung disease and we believe that by reducing the dose and administering it directly to the lung we can demonstrate improved dosing, tolerability and safety,” said Michael...

SARASOTA, Fla., April 29, 2024 (GLOBE NEWSWIRE) — Trump Media & Technology Group Corp. (NASDAQ: DJT) (“TMTG” or the “Company”) is highlighting actions DJT shareholders can take to prevent the lending of their shares by brokerage firms for the purpose of short selling. The Company’s shareholder base primarily consists of retail investors who hold their shares through various brokerage firms. Many of these retail shareholders invested in DJT because they support TMTG’s mission to create a free-speech beachhead against Big Tech censorship. TMTG wants to clarify that if shares are currently on loan by brokerage firms to facilitate short selling, shareholders have the option of asking their broker to recall their shares. After recalling their shares, long-term shareholders who believe in the Company’s future can then hold their...

Nasdaq CopenhagenLondon Stock Exchange        Euronext DublinOther partners                 Date        29 April 2024 Implementation of capital reduction As advised in the company announcement of 28 February 2024 “Minutes of the annual general meeting held on 28 February 2024”, it was decided at the bank´s annual general meeting to reduce the bank’s share capital by nom. DKK 784,600 by cancellation of 784,600 own shares. The deadline of the statutory notice to the bank’s creditors has expired with no claims being reported, and final registration of the capital reduction has been made with the Danish Business Authority. Following the capital reduction, Ringkjøbing Landbobank A/S’ nominal share capital is DKK 26,706,739 in 26,706,739 shares. The total maximum number of voting rights amount to 26,706,739.Kind regards Ringkjøbing...

      ENDEAVOUR PUBLISHES NOTICE OF ANNUAL GENERAL MEETING London, 29 April 2024 – Endeavour Mining plc (LSE:EDV, TSX: EDV, OTCQX: EDVMF) (“Endeavour” or the “Group” or the “Company”) announces that it will hold its 2024 Annual General Meeting (“AGM”) on 30 May 2024 at 3 pm (London time) / 10 am (Toronto time). A copy of the Notice of AGM, including the Management Information Circular and Form of Proxy have been posted or otherwise made available to shareholders, and in compliance with UK Listing Rule 9.6.1 submitted to the Financial Conduct Authority and will shortly be available for inspection via the National Storage Mechanism at https://data.fca.org.uk/#/nsm/nationalstoragemechanism. In addition, the Notice of AGM including the Management Information Circular will shortly be filed under the Company’s profile at https://www.sedarplus.ca/...